{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T14:18:10Z","timestamp":1788013090486,"version":"build-2784847793"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100007195","name":"Universit\u00e0 degli Studi di Napoli Federico II","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007195","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study examines how the choice of non-inferiority margins affects the clinical interpretation of interventional studies using the Santos et al. trial comparing high-flow nasal cannula (HFNC) with non-invasive ventilation (NIV) as a case example. We also demonstrate how Bayesian reanalysis improves interpretability by expressing non-inferiority margins on absolute and relative scales, quantifying posterior probabilities of non-inferiority and benefit, and translating these margins into patient-centred measures such as the Number Needed to Harm (NNH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Secondary Bayesian reanalysis of a previously published randomised controlled trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Multicentre paediatric intensive care units participating in the original Santos et al. study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients<\/jats:title>\n                    <jats:p>Infants with acute bronchiolitis were randomised to receive either HFNC or NIV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions<\/jats:title>\n                    <jats:p>Respiratory support via HFNC or NIV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measures<\/jats:title>\n                    <jats:p>The primary endpoint was intubation, with the intubation rate reported as a descriptive summary statistic. We re-expressed the original non-inferiority margin on the Absolute Risk Reduction (ARR) and Odds Ratio (OR) scales, estimated Bayesian probabilities of non-inferiority and benefit, and derived patient-centred metrics such as the NNH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The original analysis concluded non-inferiority using a fixed absolute margin. Our Bayesian reanalysis showed that this margin could correspond to a substantial relative tolerance when baseline risks are low; specifically, the 0.15 non-inferiority ARR margin might imply a doubling of the odds of intubation. When interpreted from a patient-centered perspective, this margin corresponds to an NNH of approximately 6.7. In other words, for every seven infants treated with HFNC instead of NIV, one additional child might require intubation who would not have needed it under standard care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Non-inferiority margins are typically derived through a combination of statistical evidence and clinical judgment. However, their interpretation may vary depending on the effect scale used, and this may not always be transparent in reporting. For this reason, integrating Bayesian methods and framing multiple noninferiority definitions improves the interpretability of trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s43441-026-00982-4","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:00:01Z","timestamp":1778763601000},"page":"1419-1428","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interpreting Non-Inferiority Across Effect Scales: A Bayesian Perspective with Clinical Translation"],"prefix":"10.1007","volume":"60","author":[{"given":"Danila","family":"Azzolina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bressan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Rashid","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Gregori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savino","family":"Spadaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"982_CR1","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1513\/AnnalsATS.202202-154RL","volume":"20","author":"B Patel","year":"2023","unstructured":"Patel B, Yver H, Woods-Hill CZ, Harhay MO, Yehya N. Elements of statistical power in pediatric critical care trials. Ann Am Thorac Soc. 2023;20:152\u20135. https:\/\/doi.org\/10.1513\/AnnalsATS.202202-154RL.","journal-title":"Ann Am Thorac Soc"},{"key":"982_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.4103\/picr.picr_245_21","volume":"13","author":"R Priya","year":"2022","unstructured":"Priya R, Pramesh CS, Aggarwal R. Non-inferiority trials. Perspect Clin Res. 2022;13:54\u20137. https:\/\/doi.org\/10.4103\/picr.picr_245_21.","journal-title":"Perspect Clin Res"},{"key":"982_CR3","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1038\/s41416-022-01937-w","volume":"127","author":"J Cuzick","year":"2022","unstructured":"Cuzick J, Sasieni P. Interpreting the results of noninferiority trials-a review. Br J Cancer. 2022;127:1755\u20139. https:\/\/doi.org\/10.1038\/s41416-022-01937-w.","journal-title":"Br J Cancer"},{"key":"982_CR4","doi-asserted-by":"publisher","first-page":"100913","DOI":"10.1016\/j.jacadv.2024.100913","volume":"3","author":"BA Redfors","year":"2024","unstructured":"Redfors BA. Case for using relative rather than absolute noninferiority margins in clinical trials. JACC Adv. 2024;3:100913. https:\/\/doi.org\/10.1016\/j.jacadv.2024.100913.","journal-title":"JACC Adv"},{"key":"982_CR5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13063-020-4070-4","volume":"21","author":"M Quartagno","year":"2020","unstructured":"Quartagno M, Walker AS, Babiker AG, Turner RM, Parmar MKB, Copas A, White IR. Handling an uncertain control group event risk in non-inferiority trials: non-inferiority frontiers and the power-stabilising transformation. Trials. 2020;21:145. https:\/\/doi.org\/10.1186\/s13063-020-4070-4","journal-title":"Trials"},{"issue":"8","key":"982_CR6","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1111\/bcp.13280","volume":"83","author":"TA Althunian","year":"2017","unstructured":"Althunian TA, Boer A, Groenwold RH, Klungel OH. Defining the noninferiority margin and analysing noninferiority: an overview. Br J Clin Pharmacol. 2017;83(8):1636.","journal-title":"Br J Clin Pharmacol"},{"key":"982_CR7","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1097\/PCC.0000000000001946","volume":"20","author":"R Sanders","year":"2019","unstructured":"Sanders R, Edwards L, Nishisaki A. Tracheal intubations for critically Ill children outside specialized centers in the United Kingdom-patient, provider, practice factors, and adverse events. Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc. 2019;20:572\u20133. https:\/\/doi.org\/10.1097\/PCC.0000000000001946.","journal-title":"Pediatr Crit Care Med J Soc Crit Care Med World Fed Pediatr Intensive Crit Care Soc"},{"key":"982_CR8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1186\/s12887-024-05058-6","volume":"24","author":"ACEZ Santos","year":"2024","unstructured":"Santos ACEZ, Caiado CM, Lopes AGD, De Fran\u00e7a GC, Eisen AKA, Oliveira DBL, De Araujo OR, De Carvalho WB. Comparison between high-flow nasal cannula (HFNC) therapy and noninvasive ventilation (NIV) in children with acute respiratory failure by bronchiolitis: a randomized controlled trial. BMC Pediatr. 2024;24:595. https:\/\/doi.org\/10.1186\/s12887-024-05058-6.","journal-title":"BMC Pediatr"},{"key":"982_CR9","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1056\/NEJMoa1714855","volume":"378","author":"D Franklin","year":"2018","unstructured":"Franklin D, Babl FE, Schlapbach LJ, Oakley E, Craig S, Neutze J, Furyk J, Fraser JF, Jones M, Whitty JA, et al. A randomized trial of high-flow oxygen therapy in infants with bronchiolitis. N Engl J Med. 2018;378:1121\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1714855.","journal-title":"N Engl J Med"},{"key":"982_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nrd1927","volume":"5","author":"DA Berry","year":"2006","unstructured":"Berry DA. Bayesian clinical trials. Nat Rev Drug Discov. 2006;5:27\u201336. https:\/\/doi.org\/10.1038\/nrd1927.","journal-title":"Nat Rev Drug Discov"},{"key":"982_CR11","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41573-023-00638-0","volume":"22","author":"SJ Ruberg","year":"2023","unstructured":"Ruberg SJ, Beckers F, Hemmings R, Honig P, Irony T, LaVange L, Lieberman G, Mayne J, Moscicki R. Application of Bayesian approaches in drug development: starting a virtuous cycle. Nat Rev Drug Discov. 2023;22:235\u201350. https:\/\/doi.org\/10.1038\/s41573-023-00638-0.","journal-title":"Nat Rev Drug Discov"},{"key":"982_CR12","doi-asserted-by":"publisher","unstructured":"Lang, T.A. and Altman, D.G. (2014). Statistical Analyses and Methods in the Published Literature: The SAMPL Guidelines*. In Guidelines for Reporting Health Research: A User's Manual (eds D. Moher, D.G. Altman, K.F. Schulz, I. Simera and E. Wager). TA, Altman DG. Statistical analyses and methods in the published literature: the sampl guidelines. Guidel Rep Health Res Users Man. 2014, 264\u201374Lang TA, Altman DG. Statistical analyses and methods in the published literature: the sampl guidelines. Guidel Rep Health Res Users Man. 2014, 264\u201374. https:\/\/doi.org\/10.1002\/9781118715598.ch25Lang","DOI":"10.1002\/9781118715598.ch25Lang"},{"key":"982_CR13","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2015","unstructured":"Core Team R. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2015."},{"key":"982_CR14","unstructured":"Goodrich B, Gabry J, Ali I, Brilleman S (2025). \u201crstanarm: Bayesian applied regression modeling via Stan.\u201d R package version 2.32.2, B, Gabry J, Ali I, Brilleman S. Rstanarm: Bayesian applied regression modeling via stan; 2024Goodrich B, Gabry J, Ali I, Brilleman S. Rstanarm: Bayesian applied regression modeling via stan; 2024. https:\/\/mc-stan.org\/rstanarm\/.Goodrich"},{"key":"982_CR15","doi-asserted-by":"publisher","first-page":"e0359","DOI":"10.1097\/CCE.0000000000000359","volume":"3","author":"PA Ross","year":"2021","unstructured":"Ross PA, Engorn BM, Newth CJL, Gordon C, Soto-Campos G, Bhalla AK. Declining procedures in pediatric critical care medicine using a national database. Crit Care Explor. 2021;3:e0359. https:\/\/doi.org\/10.1097\/CCE.0000000000000359.","journal-title":"Crit Care Explor"},{"key":"982_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/eahr.406003","volume":"40","author":"BA Sisk","year":"2018","unstructured":"Sisk BA, Kodish E Therapeutic misperceptions in early-phase cancer trials: from categorical to continuous. IRB. 2018;40:13\u201320. . https:\/\/doi.org\/10.1002\/eahr.406003.","journal-title":"IRB"},{"key":"982_CR17","doi-asserted-by":"publisher","first-page":"101021","DOI":"10.1016\/j.jacadv.2024.101021","volume":"3","author":"A Greco","year":"2024","unstructured":"Greco A, Spagnolo M, Laudani C, Occhipinti G, Mauro MS, Agnello F, Faro DC, Legnazzi M, Rochira C, Scalia L, et al. Assessment of noninferiority margins in cardiovascular medicine trials. JACC Adv. 2024;3:101021. https:\/\/doi.org\/10.1016\/j.jacadv.2024.101021.","journal-title":"JACC Adv"},{"key":"982_CR18","doi-asserted-by":"publisher","first-page":"e081123","DOI":"10.1136\/bmj-2024-081123","volume":"389","author":"S Hopewell","year":"2025","unstructured":"Hopewell S, Chan A-W, Collins GS, Hr\u00f3bjartsson A, Moher D, Schulz KF, Tunn R, Aggarwal R, Berkwits M, Berlin JA, et al. CONSORT 2025 statement: updated guideline for reporting randomised trials. BMJ. 2025;389:e081123. https:\/\/doi.org\/10.1136\/bmj-2024-081123.","journal-title":"BMJ"},{"key":"982_CR19","doi-asserted-by":"publisher","first-page":"2594","DOI":"10.1001\/jama.2012.87802","volume":"308","author":"G Piaggio","year":"2012","unstructured":"Piaggio G, Elbourne DR, Pocock SJ, Evans SJW, Altman DG. CONSORT group reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA. 2012;308:2594\u2013604. https:\/\/doi.org\/10.1001\/jama.2012.87802.","journal-title":"JAMA"},{"key":"982_CR20","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1136\/bmj.330.7499.1080","volume":"330","author":"CJ Gill","year":"2005","unstructured":"Gill CJ, Sabin L, Schmid CH. Why clinicians are natural Bayesians. BMJ. 2005;330:1080\u20133. https:\/\/doi.org\/10.1136\/bmj.330.7499.1080.","journal-title":"BMJ"},{"key":"982_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2025.06.052","author":"TA Demirtakan","year":"2025","unstructured":"Demirtakan TA, A Trending approach for analysis in critical care research bayesian statistics. Am J Emerg Med. 2025. https:\/\/doi.org\/10.1016\/j.ajem.2025.06.052.","journal-title":"Am J Emerg Med"}],"container-title":["Therapeutic Innovation &amp; Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-00982-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-026-00982-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-026-00982-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T13:47:12Z","timestamp":1788011232000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-026-00982-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["982"],"URL":"https:\/\/doi.org\/10.1007\/s43441-026-00982-4","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"1 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study is a secondary Bayesian reanalysis of publicly available, previously published trial data. No new data were collected, and no direct contact with patients or families occurred. Therefore, informed consent was not required.","order":2,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}